Billionaire Investor Cuts Tylenol Maker Kenvue Stake By 64%

Benzinga02:19

Hedge fund billionaire Daniel Loeb slashed his stake in the consumer health company Kenvue Inc. (NYSE:KVUE) at Third Point LLC in the fourth quarter of FY25.

As of Dec. 31, 2025, Loeb reduced his stake in the company by 64% to 3.25 million shares from about 9.0 million shares in the third quarter of 2025.

Notably, Kenvue was formerly a part of Johnson & Johnson (NYSE:JNJ) before becoming an independent company in August 2023. The company's major products include several J&J brands, including Tylenol, Listerine, Neutrogena, and Nicorette.

Recent Key Events

  • In February, Kenvue reported fourth-quarter earnings of 27 cents per share, which beat the consensus of 22 cents. The company reported sales of $3.780 billion, which exceeded the consensus estimate of $3.681 billion.
  • The company’s Board approved an initiative to streamline its operating model, which is expected to reduce the workforce by approximately 3.5%. The program is projected to incur pre-tax restructuring and related charges of about $250 million in fiscal year 2026.
  • Kenvue said it is moving forward with its acquisition process by Kimberly-Clark Corporation (NYSE:KMB). Kenvue and Kimberly-Clark shareholders overwhelmingly approved the proposals necessary for Kimberly-Clark to complete its acquisition of Kenvue, with approximately 99% of shares voted in favor at Kenvue's Special Meeting. The transaction is expected to close in the second half of 2026, pending regulatory approvals.
  • In November 2025, Kimberly-Clark announced the acquisition of Kenvue at an enterprise value of about $48.7 billion.

Technical Analysis

Kenvue is sitting in the lower half of its $14.02 to $25.17 52-week range, which keeps the longer-term chart in "repair mode" after last year's slide. The stock is trading 1.2% above its 20-day simple moving average (SMA) but 0.1% below its 100-day SMA, a setup that points to short-term stabilization without a clean intermediate uptrend.

Earnings & Analyst Outlook

The countdown is on: Kenvue is set to report earnings on May 7, 2026 (confirmed).

  • EPS Estimate: 26 cents (Up from 24 cents)
  • Revenue Estimate: $3.85 billion (Up from $3.74 billion)
  • Valuation: P/E of 23.0x (Indicates fair valuation)

Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $18.20. Recent analyst moves include:

Recent analyst moves include:

  • Citigroup: Neutral (Lowers Target to $19.00) (April 15)
  • Barclays: Equal-Weight (Lowers Target to $18.00) (April 14)
  • UBS: Neutral (Lowers Target to $18.00) (April 7)

KVUE Stock Price Activity: Kenvue shares were down 0.14% at $17.46 at the time of publication on Friday, according to Benzinga Pro data.

Photo via Shutterstock 

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment